216 related articles for article (PubMed ID: 31641562)
1. Sensorineural Hearing Loss and Its Relationship with Duration of Chelation Among Major β-Thalassemia Patients.
Khan MA; Khan MA; Seedat AM; Khan M; Khuwaja SF; Kumar R; Usama SM; Fareed S
Cureus; 2019 Aug; 11(8):e5465. PubMed ID: 31641562
[TBL] [Abstract][Full Text] [Related]
2. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
[TBL] [Abstract][Full Text] [Related]
3. Audiologic and vestibular assessment in children and adolescents with transfusion dependent beta thalassemia major: The era of deferasirox film coated tablet.
Galhom DH; Talaat RM; Hanna D; Gad NH
Int J Pediatr Otorhinolaryngol; 2024 Feb; 177():111868. PubMed ID: 38252990
[TBL] [Abstract][Full Text] [Related]
4. New Advances in Evaluation of Hearing in a Sample of Egyptian Children with β-Thalassemia Major.
Alzaree FA; Shehata MA; Atti MA; Elzaree GA; El-Kassas GM
Open Access Maced J Med Sci; 2019 May; 7(9):1494-1498. PubMed ID: 31198461
[TBL] [Abstract][Full Text] [Related]
5. Cochlear implant in Thalassemia patient - Case report.
Kataria T; Grover M; Sharma S; Samdani S; Sharma MP
Cochlear Implants Int; 2019 Jan; 20(1):47-50. PubMed ID: 30232935
[TBL] [Abstract][Full Text] [Related]
6. Sensory neural hearing loss in beta-thalassemia major patients treated with deferoxamine.
Shamsian BS; Aminasnafi A; Moghadassian H; Gachkar L; Arzanian MT; Alavi S; Esfehani H; Garallahi F; Amini R
Pediatr Hematol Oncol; 2008 Sep; 25(6):502-8. PubMed ID: 18728969
[TBL] [Abstract][Full Text] [Related]
7. The Prevalence of Sensorineural Hearing Loss in β-thalassaemia patient treated with Desferrioxamine.
Kong MH; Goh BS; Hamidah A; Zarina AL
Med J Malaysia; 2014 Feb; 69(1):9-12. PubMed ID: 24814621
[TBL] [Abstract][Full Text] [Related]
8. Sensorineural hearing loss in patients with chronic suppurative otitis media: Is there a significant correlation?
Amali A; Hosseinzadeh N; Samadi S; Nasiri S; Zebardast J
Electron Physician; 2017 Feb; 9(2):3823-3827. PubMed ID: 28465813
[TBL] [Abstract][Full Text] [Related]
9. Long term audiological evaluation of beta-thalassemic patients.
Kontzoglou G; Koussi A; Economou M; Tsatra I; Perifanis V; Noussios G; Athanassiou-Metaxa M
Acta Otorhinolaryngol Belg; 2004; 58(2):113-7. PubMed ID: 15515654
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the incidence of sensorineural hearing loss in beta-thalassemia major patients under regular chelation therapy with desferrioxamine.
Karimi M; Asadi-Pooya AA; Khademi B; Asadi-Pooya K; Yarmohammadi H
Acta Haematol; 2002; 108(2):79-83. PubMed ID: 12187025
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Hagag AA; Hamam MA; Taha OA; Hazaa SM
Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
[TBL] [Abstract][Full Text] [Related]
12. Mucosal Type of Chronic Suppurative Otitis Media and the Long-Term Impact on Hearing Loss.
Rajput MS; Rajput MSA; Arain AA; Zaidi SS; Hatem A; Akram S
Cureus; 2020 Sep; 12(9):e10176. PubMed ID: 33029456
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and adverse effects of oral chelating therapy (deferasirox) in multi-transfused Pakistani children with β-thalassemia major.
Ejaz MS; Baloch S; Arif F
Pak J Med Sci; 2015; 31(3):621-5. PubMed ID: 26150856
[TBL] [Abstract][Full Text] [Related]
14. Sensorineural hearing loss in β-thalassemia patients treated with iron chelation.
Osma U; Kurtoglu E; Eyigor H; Yilmaz MD; Aygener N
Ear Nose Throat J; 2015 Dec; 94(12):481-5. PubMed ID: 26670754
[TBL] [Abstract][Full Text] [Related]
15. Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma.
Chen WC; Jackson A; Budnick AS; Pfister DG; Kraus DH; Hunt MA; Stambuk H; Levegrun S; Wolden SL
Cancer; 2006 Feb; 106(4):820-9. PubMed ID: 16421885
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
Karimi M; Arandi N; Haghpanah S; Ansari S; Azarkeyvan A; Bordbar M; Safaei S
Hemoglobin; 2015; 39(5):327-9. PubMed ID: 26114738
[TBL] [Abstract][Full Text] [Related]
17. Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion.
Veríssimo MP; Loggetto SR; Fabron Junior A; Baldanzi GR; Hamerschlak N; Fernandes JL; Araujo Ada S; Lobo CL; Fertrin KY; Berdoukas VA; Galanello R
Rev Bras Hematol Hemoter; 2013; 35(6):428-34. PubMed ID: 24478610
[TBL] [Abstract][Full Text] [Related]
18. Auditory cortex hypoperfusion: a metabolic hallmark in Beta Thalassemia.
Manara R; Ponticorvo S; Perrotta S; Barillari MR; Costa G; Brotto D; Di Concilio R; Ciancio A; De Michele E; Carafa PA; Canna A; Russo AG; Troisi D; Caiazza M; Ammendola F; Roberti D; Santoro C; Picariello S; Valentino MS; Inserra E; Carfora R; Cirillo M; Raimo S; Santangelo G; di Salle F; Esposito F; Tartaglione I
Orphanet J Rare Dis; 2021 Aug; 16(1):349. PubMed ID: 34353346
[TBL] [Abstract][Full Text] [Related]
19. Final adult height and endocrine complications in young adults with β-thalassemia major (TM) who received oral iron chelation (OIC) in comparison with those who did not use OIC.
Soliman AT; Yassin MA; De Sanctis V
Acta Biomed; 2018 Feb; 89(2-S):27-32. PubMed ID: 29451226
[TBL] [Abstract][Full Text] [Related]
20. Frequency of Sensorineural hearing loss in chronic suppurative otitis media.
Ali Zaidi SS; Pasha HA; Suhail A; Qureshi TA
J Pak Med Assoc; 2016 Oct; 66(Suppl 3)(10):S42-S44. PubMed ID: 27895351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
